KR100509311B1 - Ｎ-치환된 2-시아노피롤리딘 - Google Patents
Ｎ-치환된 2-시아노피롤리딘 Download PDFInfo
- Publication number
- KR100509311B1 KR100509311B1 KR10-2001-7007227A KR20017007227A KR100509311B1 KR 100509311 B1 KR100509311 B1 KR 100509311B1 KR 20017007227 A KR20017007227 A KR 20017007227A KR 100509311 B1 KR100509311 B1 KR 100509311B1
- Authority
- KR
- South Korea
- Prior art keywords
- formula
- compounds
- pharmaceutically acceptable
- adamantyl
- dpp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20906898A | 1998-12-10 | 1998-12-10 | |
| US09/209,068 | 1998-12-10 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020057007771A Division KR20050047561A (ko) | 1998-12-10 | 1999-12-09 | Ｎ-치환된 2-시아노피롤리딘 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20010080740A KR20010080740A (ko) | 2001-08-22 |
| KR100509311B1 true KR100509311B1 (ko) | 2005-08-23 |
Family
ID=22777194
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR10-2001-7007227A Expired - Lifetime KR100509311B1 (ko) | 1998-12-10 | 1999-12-09 | Ｎ-치환된 2-시아노피롤리딘 |
| KR1020057007771A Ceased KR20050047561A (ko) | 1998-12-10 | 1999-12-09 | Ｎ-치환된 2-시아노피롤리딘 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020057007771A Ceased KR20050047561A (ko) | 1998-12-10 | 1999-12-09 | Ｎ-치환된 2-시아노피롤리딘 |
Country Status (34)
Families Citing this family (309)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL141967A0 (en) * | 1998-09-17 | 2002-03-10 | Akesis Pharm Inc | Combinations of chromium or vanadium with antidiabetics for glucose metabolism disorders |
| US6376549B1 (en) * | 1998-09-17 | 2002-04-23 | Akesis Pharmaceuticals, Inc. | Metforimin-containing compositions for the treatment of diabetes |
| DE19940130A1 (de) * | 1999-08-24 | 2001-03-01 | Probiodrug Ges Fuer Arzneim | Neue Effektoren der Dipeptidyl Peptidase IV zur topischen Anwendung |
| US20040152745A1 (en) * | 1999-11-12 | 2004-08-05 | Guilford Pharmaceuticals, Inc. | Dipeptidyl peptidase IV inhibitors and methods of making and using dipeptidyl peptidase IV inhibitors |
| JP2003535034A (ja) * | 1999-11-12 | 2003-11-25 | ギルフォード ファーマシューティカルズ インコーポレイテッド | ジペプチジルペプチダーゼｉｖ阻害剤並びにジペプチジルペプチダーゼｉｖ阻害剤の製造及び使用法 |
| GB9928330D0 (en) | 1999-11-30 | 2000-01-26 | Ferring Bv | Novel antidiabetic agents |
| KR20020063260A (ko) * | 1999-12-23 | 2002-08-01 | 노파르티스 아게 | 당 대사 장애를 치료하기 위한 혈당강하제의 용도 |
| US6380398B2 (en) | 2000-01-04 | 2002-04-30 | Novo Nordisk A/S | Therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV |
| EP1741445B1 (en) * | 2000-01-21 | 2013-08-14 | Novartis AG | Combinations comprising dipeptidylpeptidase-IV inhibitors and antidiabetic agents |
| US20080076811A1 (en) * | 2000-01-21 | 2008-03-27 | Bork Balkan | Combinations comprising depeptidypeptidase-iv inhibitors and antidiabetic agents |
| EP1254113A1 (en) * | 2000-01-24 | 2002-11-06 | Novo Nordisk A/S | N-substituted 2-cyanopyroles and -pyrrolines which are inhibitors of the enzyme dpp-iv |
| US6395767B2 (en) | 2000-03-10 | 2002-05-28 | Bristol-Myers Squibb Company | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
| US6432969B1 (en) | 2000-06-13 | 2002-08-13 | Novartis Ag | N-(substituted glycyl)-2 cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
| AU6895801A (en) | 2000-07-04 | 2002-01-14 | Novo Nordisk As | Heterocyclic compounds, which are inhibitors of the enzyme dpp-iv |
| PE20020617A1 (es) * | 2000-08-22 | 2002-08-05 | Novartis Ag | Composicion que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina o un sensibilizante a la insulina |
| US20060089389A1 (en) * | 2000-08-22 | 2006-04-27 | Malcolm Allison | Combination |
| US6770620B2 (en) | 2000-09-18 | 2004-08-03 | Sanos Bioscience A/S | Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders |
| US7371721B2 (en) * | 2000-09-18 | 2008-05-13 | Sanos Bioscience A/S | Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes |
| US20080249016A1 (en) * | 2000-09-18 | 2008-10-09 | Sanos Bioscience A/S | Use of GLP-2 in a combination treatment for bone-related disorders |
| US20070135345A1 (en) * | 2000-09-18 | 2007-06-14 | Henriksen Dennis B | Use of GLP-2 for the treatment or prevention, of bone-related disorders |
| IL154893A0 (en) | 2000-10-06 | 2003-10-31 | Tanabe Seiyaku Co | Aliphatic nitrogen-containing cyclic compounds, methods for the preparation thereof and pharmaceutical compositions containing the same |
| UA74023C2 (en) * | 2000-11-10 | 2005-10-17 | Taisho Pharmaceutical Co Ltd | Cyanopyrrolidine derivatives |
| TWI243162B (en) * | 2000-11-10 | 2005-11-11 | Taisho Pharmaceutical Co Ltd | Cyanopyrrolidine derivatives |
| JPWO2002051836A1 (ja) * | 2000-12-27 | 2004-04-22 | 協和醗酵工業株式会社 | ジペプチジルペプチダーゼ−ｉｖ阻害剤 |
| GB0109146D0 (en) * | 2001-04-11 | 2001-05-30 | Ferring Bv | Treatment of type 2 diabetes |
| US20030060494A1 (en) * | 2001-05-18 | 2003-03-27 | Nobuyuki Yasuda | Pharmaceutical use of N-carbamoylazole derivatives |
| WO2003000181A2 (en) | 2001-06-20 | 2003-01-03 | Merck & Co., Inc. | Dipeptidyl peptidase inhibitors for the treatment of diabetes |
| AU2002344820B2 (en) | 2001-06-20 | 2006-12-14 | Merck & Co., Inc. | Dipeptidyl peptidase inhibitors for the treatment of diabetes |
| WO2003002530A2 (en) | 2001-06-27 | 2003-01-09 | Smithkline Beecham Corporation | Pyrrolidines as dipeptidyl peptidase inhibitors |
| EP1399433B1 (en) * | 2001-06-27 | 2007-08-22 | Smithkline Beecham Corporation | Fluoropyrrolidines as dipeptidyl peptidase inhibitors |
| DE60222667T2 (de) * | 2001-06-27 | 2008-07-17 | Smithkline Beecham Corp. | Fluorpyrrolidine als dipeptidylpeptidaseinhibitoren |
| US6709651B2 (en) * | 2001-07-03 | 2004-03-23 | B.M.R.A. Corporation B.V. | Treatment of substance P-related disorders |
| UA74912C2 (en) * | 2001-07-06 | 2006-02-15 | Merck & Co Inc | Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes |
| US6861440B2 (en) | 2001-10-26 | 2005-03-01 | Hoffmann-La Roche Inc. | DPP IV inhibitors |
| EP1470246A2 (en) * | 2001-10-31 | 2004-10-27 | Novartis AG | Methods to treat diabetes and related conditions based on polymorphisms in the tcf1 gene |
| US20050101638A1 (en) * | 2002-11-08 | 2005-05-12 | Webb Randy L. | Combination of organic compounds |
| US20030135663A1 (en) * | 2002-01-16 | 2003-07-17 | Sun Microsystems, Inc. | Method, system, and program for including device parameters from a device driver in a configuration file |
| RU2293731C2 (ru) | 2002-02-13 | 2007-02-20 | Ф.Хоффманн-Ля Рош Аг | Производные пиридина и пиримидина, способы их получения (варианты), фармацевтическая композиция и применение |
| RU2285693C2 (ru) | 2002-02-13 | 2006-10-20 | Ф.Хоффманн-Ля Рош Аг | Производные пиридина и хинолина, способ их получения, фармацевтическая композиция, применение соединений для лечения заболеваний, ассоциированных с dpp-iv |
| DE60304911D1 (de) | 2002-02-25 | 2006-06-08 | Eisai Co Ltd | Xanthin-Derivate als DPP-IV-Inhibitoren |
| CA2478389A1 (en) * | 2002-03-25 | 2003-10-09 | Merck & Co., Inc. | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| CN100402026C (zh) * | 2002-06-03 | 2008-07-16 | 诺瓦提斯公司 | 取代的氰基吡咯烷和含有它们的组合制剂用于治疗高脂血症和相关疾病的用途 |
| US6710040B1 (en) * | 2002-06-04 | 2004-03-23 | Pfizer Inc. | Fluorinated cyclic amides as dipeptidyl peptidase IV inhibitors |
| JP2004026678A (ja) * | 2002-06-24 | 2004-01-29 | Microbial Chem Res Found | ２型糖尿病治療剤 |
| AU2003248259A1 (en) * | 2002-07-10 | 2004-02-02 | Yamanouchi Pharmaceutical Co., Ltd. | Novel azetidine derivative or salt thereof |
| US7208498B2 (en) * | 2002-07-15 | 2007-04-24 | Merck & Co., Inc. | Piperidino pyrimidine dipeptidyl peptidase inhibitors for the treatment of diabetes |
| TW200401635A (en) * | 2002-07-23 | 2004-02-01 | Yamanouchi Pharma Co Ltd | 2-Cyano-4-fluoropyrrolidine derivative or salt thereof |
| US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| WO2004026822A2 (en) * | 2002-09-19 | 2004-04-01 | Abbott Laboratories | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-iv (dpp-iv) |
| ATE370141T1 (de) | 2002-10-07 | 2007-09-15 | Merck & Co Inc | Antidiabetische heterocyclische beta- aminoverbindungen als inhibitoren von dipeptidylpeptidase |
| KR20050067418A (ko) * | 2002-10-18 | 2005-07-01 | 머크 앤드 캄파니 인코포레이티드 | 당뇨병을 치료 또는 예방하기 위한 베타-아미노헤테로사이클릭 디펩티딜 펩티다제 억제제 |
| JP4413863B2 (ja) | 2002-11-07 | 2010-02-10 | メルク エンド カムパニー インコーポレーテッド | 糖尿病の治療又は予防のためのジペチジルペプチダーゼ阻害剤としてのフェニルアラニン誘導体 |
| EP1578414A4 (en) * | 2002-12-04 | 2007-10-24 | Merck & Co Inc | PHENYLALANINE DERIVATIVES ALSDIPEPTIDYL-PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES |
| CA2508947A1 (en) * | 2002-12-20 | 2004-07-15 | Merck & Co., Inc. | 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| DK1599468T3 (da) | 2003-01-14 | 2008-02-04 | Arena Pharm Inc | 1,2,3-trisubstituerede aryl- og heteroarylderivater som modulatorer af metabolisme og forebyggelse og behandling af forstyrrelser forbundet dermed såsom diabetes og hyperglykæmi |
| JP4564952B2 (ja) | 2003-01-17 | 2010-10-20 | メルク・シャープ・エンド・ドーム・コーポレイション | 糖尿病の治療および予防のためのジペプチジルペプチダーゼ阻害薬としての３−アミノ−４−フェニルブタン酸誘導体 |
| AU2004210149A1 (en) * | 2003-01-31 | 2004-08-19 | Merck & Co., Inc. | 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| US7550590B2 (en) | 2003-03-25 | 2009-06-23 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| GB0308854D0 (en) * | 2003-04-16 | 2003-05-21 | Novartis Ag | Organic compounds |
| AR044019A1 (es) * | 2003-04-16 | 2005-08-24 | Novartis Ag | Proceso para la preparacion de 2-cianopirrolidinas n-sustituidas |
| US7560455B2 (en) * | 2003-05-14 | 2009-07-14 | Merck & Co., Inc. | 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| WO2004103993A1 (en) | 2003-05-14 | 2004-12-02 | Syrrx, Inc. | Dipeptidyl peptidase inhibitors |
| EP1635818B1 (en) * | 2003-06-06 | 2010-04-07 | Merck Sharp & Dohme Corp. | Fused indoles as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| CN1809544A (zh) | 2003-06-17 | 2006-07-26 | 麦克公司 | 作为二肽基肽酶抑制剂用于治疗或预防糖尿病的环己基甘氨酸衍生物 |
| DE602004030244D1 (de) | 2003-06-20 | 2011-01-05 | Hoffmann La Roche | Itoren |
| CN101090901B (zh) | 2003-06-20 | 2010-12-15 | 霍夫曼-拉罗奇有限公司 | 作为dpp-iv抑制剂的六氢吡啶并异喹啉类 |
| AR045047A1 (es) | 2003-07-11 | 2005-10-12 | Arena Pharm Inc | Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos |
| AU2004261186A1 (en) | 2003-07-31 | 2005-02-10 | Merck & Co., Inc. | Hexahydrodiazepinones as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes |
| US6995183B2 (en) | 2003-08-01 | 2006-02-07 | Bristol Myers Squibb Company | Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods |
| US7169926B1 (en) | 2003-08-13 | 2007-01-30 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| US20050070531A1 (en) | 2003-08-13 | 2005-03-31 | Syrrx, Inc. | Dipeptidyl peptidase inhibitors |
| US7678909B1 (en) | 2003-08-13 | 2010-03-16 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| WO2005026148A1 (en) | 2003-09-08 | 2005-03-24 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
| AR046330A1 (es) * | 2003-09-09 | 2005-12-07 | Japan Tobacco Inc | Inhibidor de dipeptidilpeptidasa iv |
| WO2005033099A2 (en) * | 2003-10-03 | 2005-04-14 | Glenmark Pharmaceuticals Ltd. | Novel dipeptidyl peptidase iv inhibitors; processes for their preparation and compositions thereof |
| WO2005049027A2 (en) * | 2003-11-03 | 2005-06-02 | Probiodrug Ag | Combinations useful for the treatment of neuronal disorders |
| CA2541212A1 (en) * | 2003-11-04 | 2005-05-19 | Wallace T. Ashton | Fused phenylalanine derivatives as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
| US7576121B2 (en) * | 2003-11-12 | 2009-08-18 | Phenomix Corporation | Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
| US7317109B2 (en) | 2003-11-12 | 2008-01-08 | Phenomix Corporation | Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
| US7767828B2 (en) * | 2003-11-12 | 2010-08-03 | Phenomix Corporation | Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
| PT1689757E (pt) * | 2003-11-12 | 2014-12-09 | Sino Med Internat Alliance Inc | Compostos heterocíclicos de ácido borónico |
| RU2385723C2 (ru) * | 2003-11-17 | 2010-04-10 | Новартис Аг | Применение ингибиторов дипептидилпептидазы iv |
| KR20150028829A (ko) * | 2003-11-17 | 2015-03-16 | 노파르티스 아게 | 디펩티딜 펩티다제 ⅳ 억제제의 용도 |
| BR122018014389B1 (pt) * | 2004-01-20 | 2023-04-25 | Novartis Ag | Processo para preparar comprimido farmacêutico por compressão direta |
| KR101130433B1 (ko) * | 2004-02-05 | 2012-03-27 | 교린 세이야꾸 가부시키 가이샤 | 비시클로에스테르 유도체 |
| US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
| AU2005212073B2 (en) * | 2004-02-18 | 2010-07-08 | Kyorin Pharmaceutical Co., Ltd. | Bicyclic amide derivatives |
| WO2005079795A2 (en) * | 2004-02-20 | 2005-09-01 | Novartis Ag | Dpp-iv inhibitors for treating neurodegeneration and cognitive disorders |
| CA2557275C (en) * | 2004-02-27 | 2012-06-05 | Kyorin Pharmaceutical Co., Ltd. | Bicyclo derivative |
| US7687504B2 (en) * | 2004-03-09 | 2010-03-30 | National Health Research Institutes | Pyrrolidine compounds |
| US7732446B1 (en) | 2004-03-11 | 2010-06-08 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| CN102140090A (zh) | 2004-03-15 | 2011-08-03 | 武田药品工业株式会社 | 二肽基肽酶抑制剂 |
| US7741082B2 (en) * | 2004-04-14 | 2010-06-22 | Bristol-Myers Squibb Company | Process for preparing dipeptidyl peptidase IV inhibitors and intermediates therefor |
| TW200604167A (en) * | 2004-04-27 | 2006-02-01 | Astellas Pharma Inc | Pyrrolidine derivatives |
| US7687492B2 (en) | 2004-05-04 | 2010-03-30 | Merck Sharp & Dohme Corp. | 1,2,4-Oxadiazole derivatives as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes |
| EP1756106A4 (en) | 2004-05-18 | 2008-12-17 | Merck & Co Inc | CYCLOHEXYLALANINE DERIVATIVES AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-IV FOR THE TREATMENT OR PREVENTION OF DIABETES |
| JP2008501714A (ja) | 2004-06-04 | 2008-01-24 | 武田薬品工業株式会社 | ジペプチジルペプチダーゼインヒビター |
| US7935723B2 (en) * | 2004-06-04 | 2011-05-03 | Novartis Pharma Ag | Use of organic compounds |
| JP2008505975A (ja) | 2004-07-12 | 2008-02-28 | フェノミックス コーポレーション | 制約されたシアノ化合物 |
| WO2006019965A2 (en) | 2004-07-16 | 2006-02-23 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
| AU2005267093B2 (en) | 2004-07-23 | 2009-10-01 | Nuada Llc | Peptidase inhibitors |
| TW200608967A (en) | 2004-07-29 | 2006-03-16 | Sankyo Co | Pharmaceutical compositions containing with diabetic agent |
| AR050615A1 (es) * | 2004-08-27 | 2006-11-08 | Novartis Ag | Composiciones farmaceuticas para la administracion oral |
| KR20070073887A (ko) | 2004-10-12 | 2007-07-10 | 그렌마크 파머수티칼스 에스. 아. | 신규한 디펩티딜 펩티다제 ⅳ 억제제, 이를 함유하는약제학적 조성물, 및 이의 제조공정 |
| AU2005299808B2 (en) * | 2004-10-25 | 2009-08-20 | Novartis Ag | Combination of DPP-IV inhibitor, PPAR antidiabetic and metformin |
| DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
| CN101090888A (zh) | 2004-12-20 | 2007-12-19 | 霍夫曼-拉罗奇有限公司 | 4－氨基哌啶衍生物 |
| US7411093B2 (en) | 2004-12-20 | 2008-08-12 | Hoffman-La Roche Inc. | Aminocycloalkanes as DPP-IV inhibitors |
| JP2008524331A (ja) | 2004-12-21 | 2008-07-10 | 武田薬品工業株式会社 | ジペプチジルペプチダーゼ阻害剤 |
| DOP2006000008A (es) | 2005-01-10 | 2006-08-31 | Arena Pharm Inc | Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1 |
| GT200600008A (es) * | 2005-01-18 | 2006-08-09 | Formulacion de compresion directa y proceso | |
| JP2008024592A (ja) * | 2005-01-28 | 2008-02-07 | Taisho Pharmaceut Co Ltd | シアノピロリジン誘導体含有固形製剤用組成物、それを含有する固形製剤及びその製造方法 |
| WO2006090244A1 (en) * | 2005-02-22 | 2006-08-31 | Glenmark Pharmaceuticals S.A. | New adamantane derivatives as dipeptidyl, peptidase iv inhibitors, processes for their preparation, and pharmaceutical compositions containing them |
| TWI357902B (en) | 2005-04-01 | 2012-02-11 | Lg Life Science Ltd | Dipeptidyl peptidase-iv inhibiting compounds, meth |
| CN101277949A (zh) * | 2005-04-22 | 2008-10-01 | 阿兰托斯制药控股公司 | 二肽基肽酶-ⅳ抑制剂 |
| US7825139B2 (en) | 2005-05-25 | 2010-11-02 | Forest Laboratories Holdings Limited (BM) | Compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
| EP1888101B1 (en) | 2005-06-06 | 2012-03-21 | Georgetown University | Compositions and methods for lipo modeling |
| MY152185A (en) | 2005-06-10 | 2014-08-29 | Novartis Ag | Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation |
| EP1912706A4 (en) * | 2005-06-17 | 2009-05-27 | Aurigene Discovery Technologie | NEW 5-SUBSTITUTED INDOL DERIVATIVES AS DIPEPTIDYL-PEPTIDASE IV (DPP-IV) HEMMER |
| JP2009501192A (ja) * | 2005-07-12 | 2009-01-15 | ノバルティス アクチエンゲゼルシャフト | 有機化合物の組み合わせ |
| DE102005035891A1 (de) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
| RU2008107873A (ru) * | 2005-08-04 | 2009-09-10 | Новартис АГ (CH) | Новые соединения |
| GT200600381A (es) | 2005-08-25 | 2007-03-28 | Compuestos organicos | |
| JP5027137B2 (ja) | 2005-09-14 | 2012-09-19 | 武田薬品工業株式会社 | ジペプチジルペプチダーゼ阻害剤の投与 |
| KR101368988B1 (ko) | 2005-09-16 | 2014-02-28 | 다케다 야쿠힌 고교 가부시키가이샤 | 디펩티딜 펩티다제 억제제 |
| TW200738266A (en) * | 2005-09-29 | 2007-10-16 | Sankyo Co | Pharmaceutical agent containing insulin resistance improving agent |
| JOP20180109A1 (ar) * | 2005-09-29 | 2019-01-30 | Novartis Ag | تركيبة جديدة |
| WO2007041833A1 (en) * | 2005-10-07 | 2007-04-19 | Waratah Pharmaceuticals, Inc. | Combined use of dpp iv inhibitors and gastrin compounds |
| GB0526291D0 (en) | 2005-12-23 | 2006-02-01 | Prosidion Ltd | Therapeutic method |
| CA2635399A1 (en) * | 2006-01-06 | 2007-10-25 | Novartis Ag | Use.of vildagliptin for the treatment of diabetes |
| EP1995237A4 (en) | 2006-03-08 | 2011-07-06 | Kyorin Seiyaku Kk | PROCESS FOR PREPARING AN AMINOACETYLPYRROLIDINCARBONITRILE DERIVATIVE AND PRODUCTION PRODUCT THEREOF |
| CA2646598C (en) | 2006-03-21 | 2014-08-19 | Amylin Pharmaceuticals, Inc. | Peptide-peptidase inhibitor conjugates and methods of using same |
| WO2007112347A1 (en) | 2006-03-28 | 2007-10-04 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| RU2443687C2 (ru) * | 2006-04-03 | 2012-02-27 | Матрикс Лэборетериз Лтд. | Новые ингибиторы дипептидилпептидазы iv, способы их получения и содержащие их фармацевтические композиции |
| JP2009532454A (ja) * | 2006-04-03 | 2009-09-10 | マトリックス ラボラトリーズ リミテッド | 新規ジペプチジルペプチダーゼｉｖ阻害因子およびその調製方法、ならび該阻害因子を含む医薬組成物 |
| BRPI0710597A2 (pt) | 2006-04-11 | 2012-06-19 | Arena Pharm Inc | método de uso do receptor gpr119 para identificar compostos úteis para aumento da massa óssea em um indivìduo |
| PE20071221A1 (es) | 2006-04-11 | 2007-12-14 | Arena Pharm Inc | Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas |
| EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
| BRPI0711558A2 (pt) | 2006-05-04 | 2011-11-08 | Boeringer Ingelheim Internat Gmbh | polimorfos |
| PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
| EP2636680A3 (en) | 2006-05-26 | 2013-12-11 | Amylin Pharmaceuticals, LLC | Composition and methods for treatment of congestive heart failure |
| EP2213289A1 (en) | 2006-09-07 | 2010-08-04 | Nycomed GmbH | Combination treatment for diabetes mellitus |
| US8324383B2 (en) | 2006-09-13 | 2012-12-04 | Takeda Pharmaceutical Company Limited | Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile |
| PE20081150A1 (es) * | 2006-09-13 | 2008-10-03 | Takeda Pharmaceutical | Inhibidores de dipetidilpeptidasa |
| TW200838536A (en) | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
| US20080167479A1 (en) * | 2007-01-10 | 2008-07-10 | Medichem, S.A. | Process for preparing vildagliptin |
| US8093236B2 (en) | 2007-03-13 | 2012-01-10 | Takeda Pharmaceuticals Company Limited | Weekly administration of dipeptidyl peptidase inhibitors |
| US20080064701A1 (en) * | 2007-04-24 | 2008-03-13 | Ramesh Sesha | Anti-diabetic combinations |
| EP2123636B1 (en) | 2007-03-22 | 2012-03-21 | Kyorin Pharmaceutical Co., Ltd. | Method for producing aminoacetylpyrrolidinecarbonitrile derivative |
| CN101652147B (zh) | 2007-04-03 | 2013-07-24 | 田边三菱制药株式会社 | 二肽基肽酶iv抑制化合物和甜味剂的并用 |
| DE102007022007A1 (de) * | 2007-05-08 | 2008-11-13 | Schebo Biotech Ag | Neuartike Pharmazeutika, Verfahren zu ihrer Herstellung und ihre Verwendung in der Prophylaxe und Therapie von ZNS-Erkrankungen und Diabetes |
| KR101560844B1 (ko) | 2007-06-04 | 2015-10-15 | 벤-구리온 유니버시티 오브 더 네게브 리서치 앤드 디벨럽먼트 어쏘러티 | 트라이-아릴계 화합물 및 이를 포함하는 조성물 |
| PE20090938A1 (es) | 2007-08-16 | 2009-08-08 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo |
| EP3542801A1 (en) * | 2007-08-17 | 2019-09-25 | Boehringer Ingelheim International GmbH | Purin derivatives for use in the treatment of fap-related diseases |
| US8338450B2 (en) * | 2007-09-21 | 2012-12-25 | Lupin Limited | Compounds as dipeptidyl peptidase IV (DPP IV) inhibitors |
| US20090082420A1 (en) * | 2007-09-25 | 2009-03-26 | Protia, Llc | Deuterium-enriched vildagliptin |
| WO2009042922A2 (en) * | 2007-09-27 | 2009-04-02 | Amylin Pharmaceuticals, Inc. | Peptide-peptidase inhibitor conjugates and methods of making and using same |
| PT2247602E (pt) * | 2007-11-30 | 2013-07-10 | Novartis Ag | Derivados de adamantil o-glucuronido como inibidores da dipeptidilpeptidase iv para o tratamento de diabetes |
| CN101945851B (zh) | 2007-12-12 | 2012-10-31 | 阿斯利康(瑞典)有限公司 | 肽基腈和其作为二肽基肽酶i抑制剂的用途 |
| KR101105607B1 (ko) | 2007-12-21 | 2012-01-18 | 주식회사 엘지생명과학 | 디펩티딜 펩티데이즈－ｉｖ（ｄｐｐ－ｉｖ）저해용 신규 화합물, 그것의 제조방법 및 그것을 활성성분으로서 함유하는 약제 조성물 |
| CL2008003653A1 (es) | 2008-01-17 | 2010-03-05 | Mitsubishi Tanabe Pharma Corp | Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica. |
| US8551524B2 (en) * | 2008-03-14 | 2013-10-08 | Iycus, Llc | Anti-diabetic combinations |
| PE20140960A1 (es) * | 2008-04-03 | 2014-08-15 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
| EP2146210A1 (en) | 2008-04-07 | 2010-01-20 | Arena Pharmaceuticals, Inc. | Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY |
| PE20100156A1 (es) * | 2008-06-03 | 2010-02-23 | Boehringer Ingelheim Int | Tratamiento de nafld |
| WO2009155309A1 (en) * | 2008-06-19 | 2009-12-23 | Concert Pharmaceuticals, Inc. | Substituted cyanopyrrolidine derivatives |
| UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
| KR20190016601A (ko) | 2008-08-06 | 2019-02-18 | 베링거 인겔하임 인터내셔날 게엠베하 | 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료 |
| JP5476305B2 (ja) * | 2008-08-07 | 2014-04-23 | 杏林製薬株式会社 | ビシクロ［２．２．２］オクチルアミン誘導体の製造方法 |
| RU2011108420A (ru) * | 2008-08-14 | 2012-09-20 | Киорин Фармасьютикал Ко., Лтд. (Jp) | Стабилизированный фармацевтический состав |
| AU2009281122C1 (en) * | 2008-08-15 | 2016-04-21 | Boehringer Ingelheim International Gmbh | Purin derivatives for use in the treatment of fab-related diseases |
| CZ2008512A3 (cs) | 2008-08-26 | 2010-03-10 | Zentiva, A. S | Zpusob prípravy vysoce cistého vildagliptinu |
| WO2010029089A2 (en) | 2008-09-10 | 2010-03-18 | Boehringer Ingelheim International Gmbh | Combination therapy for the treatment of diabetes and related conditions |
| CN102850330B (zh) * | 2008-09-23 | 2014-10-15 | 成都地奥制药集团有限公司 | 经溴代的制备n取代的吡咯烷衍生物的方法 |
| US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
| JO2870B1 (en) | 2008-11-13 | 2015-03-15 | ميرك شارب اند دوهم كورب | Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes |
| AU2009331471B2 (en) | 2008-12-23 | 2015-09-03 | Boehringer Ingelheim International Gmbh | Salt forms of organic compound |
| TW201036975A (en) | 2009-01-07 | 2010-10-16 | Boehringer Ingelheim Int | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy |
| KR101750420B1 (ko) | 2009-01-09 | 2017-06-26 | 오키드 파마 리미티드 | 디펩티딜 펩티다제 ｉｖ 억제제 |
| AR075204A1 (es) | 2009-01-29 | 2011-03-16 | Boehringer Ingelheim Int | Inhibidores de dpp-4 y composiciones farmaceuticas que los comprenden, utiles para tratar enfermedades metabolicas en pacientes pediatricos, particularmente diabetes mellitus tipo 2 |
| SG173619A1 (en) | 2009-02-13 | 2011-09-29 | Boehringer Ingelheim Int | Pharmaceutical composition comprising a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof |
| AU2010212823B2 (en) | 2009-02-13 | 2016-01-28 | Boehringer Ingelheim International Gmbh | Antidiabetic medications comprising a DPP-4 inhibitor (linagliptin) optionally in combination with other antidiabetics |
| CA2756428A1 (en) | 2009-03-27 | 2010-09-30 | Mamoru Fukuda | Matrix-type sustained release preparation containing basic additive |
| EP2427445A1 (en) | 2009-05-07 | 2012-03-14 | AstraZeneca AB | Substituted 1-cyanoethylheterocyclylcarboxamide compounds 750 |
| SI2429995T1 (sl) | 2009-05-15 | 2014-05-30 | Novartis Ag | Arilpiridini kot inhibitorji aldosteron sintaze |
| CA2761853A1 (en) | 2009-05-15 | 2010-11-18 | Novartis Ag | Benzoxazolone derivatives as aldosterone synthase inhibitors |
| KR101442897B1 (ko) | 2009-05-28 | 2014-09-23 | 노파르티스 아게 | 네프릴리신 억제제로서의 치환된 아미노프로피온산 유도체 |
| EP2435402B1 (en) | 2009-05-28 | 2016-04-13 | Novartis AG | Substituted aminobutyric derivatives as neprilysin inhibitors |
| GB2483614B (en) | 2009-06-18 | 2014-12-03 | Lupin Ltd | 2-Amino-2- [8-(dimethyl carbamoyl)- 8-aza- bicyclo [3.2.1] oct-3-yl]-exo- ethanoyl derivatives as potent dpp-iv inhibitors |
| AR077642A1 (es) | 2009-07-09 | 2011-09-14 | Arena Pharm Inc | Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo |
| WO2011014520A2 (en) | 2009-07-29 | 2011-02-03 | Irm Llc | Compounds and compositions as modulators of gpr119 activity |
| WO2011012322A2 (en) | 2009-07-31 | 2011-02-03 | Krka, D.D., Novo Mesto | Synthesis and use of vildagliptin for the preparation of pharmaceutical dosage forms |
| BR112012004335A8 (pt) | 2009-09-02 | 2016-06-21 | Merck Sharp & Dohme | Composto, composição farmacêutica, e, uso do composto. |
| HUE024874T2 (en) | 2009-09-03 | 2016-02-29 | Bioenergenix | Heterocyclic compounds for the inhibition of pask |
| EP2295083A1 (de) | 2009-09-15 | 2011-03-16 | Ratiopharm GmbH | Pharmazeutische Zusammensetzung mit den Wirkstoffen Metformin und Sitagliptin oder Vildagliptin |
| JP5855568B2 (ja) | 2009-09-15 | 2016-02-09 | セルリアン・ファーマ・インコーポレイテッド | 癌の治療法 |
| HUP0900638A2 (en) | 2009-10-07 | 2011-05-30 | Egyt Gyogyszervegyeszeti Gyar | Adducts of inorganic salts basea on vildaelitpin applicable for preparation of pharmaceutical compositions |
| EA201200570A1 (ru) | 2009-10-09 | 2012-11-30 | Айрм Ллк | Соединения и композиции в качестве модуляторов активности gpr119 |
| EP2308847B1 (en) | 2009-10-09 | 2014-04-02 | EMC microcollections GmbH | Substituted pyridines as inhibitors of dipeptidyl peptidase IV and their application for the treatment of diabetes and related diseases |
| ES2551002T3 (es) | 2009-11-17 | 2015-11-13 | Novartis Ag | Derivados de aril-piridina como inhibidores de la aldosterona sintasa |
| JO2967B1 (en) | 2009-11-20 | 2016-03-15 | نوفارتس ايه جي | Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors |
| CA2781669A1 (en) | 2009-11-23 | 2011-05-26 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutic delivery |
| AU2010323068B2 (en) | 2009-11-27 | 2015-09-03 | Boehringer Ingelheim International Gmbh | Treatment of genotyped diabetic patients with DPP-IV inhibitors such as linagliptin |
| ES2472446T3 (es) | 2009-11-30 | 2014-07-01 | Novartis Ag | Derivados de imidazol como inhibidores de aldosterona sintasa |
| US8394858B2 (en) | 2009-12-03 | 2013-03-12 | Novartis Ag | Cyclohexane derivatives and uses thereof |
| JP5686413B2 (ja) | 2009-12-22 | 2015-03-18 | 塩野義製薬株式会社 | アダマンタンアミン誘導体 |
| WO2011090940A1 (en) | 2010-01-19 | 2011-07-28 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutic delivery |
| EP2538783B1 (en) | 2010-02-22 | 2016-06-01 | Merck Sharp & Dohme Corp. | Substituted aminotetrahydrothiopyrans and derivatives thereof as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes |
| CN101798270B (zh) * | 2010-02-25 | 2013-04-17 | 东华大学 | 一种3-氨基-1-金刚烷醇的制备方法 |
| EP2547339A1 (en) | 2010-03-18 | 2013-01-23 | Boehringer Ingelheim International GmbH | Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions |
| MX2012011631A (es) | 2010-04-06 | 2013-01-18 | Arena Pharm Inc | Moduladores del receptor gpr119 y el tratamiento de trastornos relacionados con el mismo. |
| JP6034781B2 (ja) | 2010-05-05 | 2016-11-30 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 併用療法 |
| EP2571876B1 (en) | 2010-05-21 | 2016-09-07 | Merck Sharp & Dohme Corp. | Substituted seven-membered heterocyclic compounds as dipeptidyl peptidase-iv inhibitors for the treatment of diabetes |
| CN102260265B (zh) | 2010-05-24 | 2015-09-02 | 上海阳帆医药科技有限公司 | 六氢吡咯[3,4-b]吡咯衍生物、其制备方法及其用途 |
| CN101870671B (zh) * | 2010-06-11 | 2012-06-27 | 漆又毛 | 金刚烷基吡咯烷衍生物及制备和应用 |
| PH12012502524A1 (en) | 2010-06-24 | 2014-02-10 | Boehringer Ingelheim Int | Diabetes therapy |
| IT1400714B1 (it) | 2010-07-06 | 2013-06-28 | Chemelectiva S R L | Processo ed intermedi per la preparazione di un principio attivo. |
| US8697739B2 (en) | 2010-07-29 | 2014-04-15 | Novartis Ag | Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof |
| EP2604591A4 (en) * | 2010-08-09 | 2015-07-22 | Shionogi & Co | PROCESS FOR THE PREPARATION OF AMINOADAMANTYL CARBAMATE DERIVATIVES |
| HU231050B1 (hu) | 2010-08-19 | 2020-02-28 | Egis Gyógyszergyár Nyrt. | Eljárás gyógyszerhatóanyag előállítására |
| JP5941916B2 (ja) | 2010-09-22 | 2016-06-29 | アリーナ ファーマシューティカルズ， インコーポレイテッド | Ｇｐｒ１１９レセプターのモジュレーターおよびそれに関連する障害の処置 |
| US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
| US8673974B2 (en) | 2010-11-16 | 2014-03-18 | Novartis Ag | Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors |
| US8877815B2 (en) | 2010-11-16 | 2014-11-04 | Novartis Ag | Substituted carbamoylcycloalkyl acetic acid derivatives as NEP |
| TR201107482A1 (tr) | 2010-12-21 | 2012-07-23 | Sanovel İlaç San.Ve Ti̇c.A.Ş. | Vildagliptin ve gliklazidin iki tabakalı kombinasyon kompozisyonu. |
| EP2468268B1 (en) | 2010-12-21 | 2017-12-13 | Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi | Combination composition of vildagliptin and gliclazide |
| TR201101809A1 (tr) | 2010-12-21 | 2012-07-23 | Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ | Vildagliptin ve glimepirid kombinasyonları. |
| TR201010683A1 (tr) | 2010-12-21 | 2012-07-23 | Sanovel İlaç San. Ve Ti̇c. A.Ş. | Vildagliptin formülasyonları. |
| EP2670486B1 (en) | 2011-01-31 | 2016-04-06 | Cadila Healthcare Limited | Treatment for lipodystrophy |
| EP2681207B1 (en) | 2011-03-02 | 2016-12-28 | Bioenergenix | Heterocyclic compounds for the inhibition of pask |
| WO2012135570A1 (en) | 2011-04-01 | 2012-10-04 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| US20140066369A1 (en) | 2011-04-19 | 2014-03-06 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
| US20140038889A1 (en) | 2011-04-22 | 2014-02-06 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
| US20140051714A1 (en) | 2011-04-22 | 2014-02-20 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
| WO2012170702A1 (en) | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| EP2729468A4 (en) | 2011-07-05 | 2015-03-18 | Merck Sharp & Dohme | Tricyclic heterocycles useful as dipeptidyl peptidase-iv inhibitors |
| HUE061596T2 (hu) | 2011-07-15 | 2023-07-28 | Boehringer Ingelheim Int | Szubsztituált dimer kinazolin származék, annak elõállítása és alkalmazása az I. és II. típusú cukorbetegség kezelésére szolgáló gyógyszerkészítményekben |
| EP2753328A1 (en) | 2011-09-07 | 2014-07-16 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Dpp-iv inhibitor formulations |
| EP2572704A1 (en) | 2011-09-22 | 2013-03-27 | Sanovel Ilac Sanayi ve Ticaret A.S. | Orally-Disintegrating Formulations of Vildagliptin |
| EP2578208B1 (en) | 2011-10-06 | 2014-05-21 | Sanovel Ilac Sanayi ve Ticaret A.S. | DPP-IV inhibitor solid dosage formulations |
| WO2013055910A1 (en) | 2011-10-12 | 2013-04-18 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
| ITMI20112224A1 (it) | 2011-12-06 | 2013-06-07 | Chemelectiva S R L | Nuovo processo ed intermedi per la sintesi di vildagliptin |
| CN102491928A (zh) * | 2011-12-13 | 2012-06-13 | 临海天宇药业有限公司 | 一种制备(2s)-n-氯乙酰基-2-氰基四氢吡咯的方法 |
| US9115082B2 (en) | 2012-01-18 | 2015-08-25 | Catherine Yang | Dipeptidyl-peptidase-IV inhibitors for treatment of type 2 diabetes complex with hypertension |
| WO2013122920A1 (en) | 2012-02-17 | 2013-08-22 | Merck Sharp & Dohme Corp. | Dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
| US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
| CN102617434B (zh) * | 2012-03-29 | 2014-07-23 | 中国科学院上海有机化学研究所 | 一锅法制备维达列汀 |
| IN2012MU01383A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * | 2012-05-04 | 2014-02-28 | ||
| JP6218811B2 (ja) | 2012-05-14 | 2017-10-25 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｓｉｒｓ及び／又は敗血症の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体 |
| WO2013171167A1 (en) | 2012-05-14 | 2013-11-21 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome |
| WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
| WO2014018350A1 (en) | 2012-07-23 | 2014-01-30 | Merck Sharp & Dohme Corp. | Treating diabetes with dipeptidyl peptidase-iv inhibitors |
| WO2014020462A1 (en) * | 2012-08-01 | 2014-02-06 | Alembic Pharmaceuticals Limited | Improved process for preparation of vildagliptin intermediate |
| WO2014052619A1 (en) | 2012-09-27 | 2014-04-03 | Irm Llc | Piperidine derivatives and compositions as modulators of gpr119 activity |
| TWI500613B (zh) | 2012-10-17 | 2015-09-21 | Cadila Healthcare Ltd | 新穎之雜環化合物 |
| WO2014074668A1 (en) | 2012-11-08 | 2014-05-15 | Arena Pharmaceuticals, Inc. | Modulators of gpr119 and the treatment of disorders related thereto |
| UY35144A (es) | 2012-11-20 | 2014-06-30 | Novartis Ag | Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca |
| CN103922986B (zh) * | 2013-01-16 | 2017-02-15 | 上海彩迩文生化科技有限公司 | 维大列汀及其类似物、中间体及其制备方法和应用 |
| BR112015019369A2 (pt) | 2013-02-14 | 2017-07-18 | Novartis Ag | derivados de ácido bisfenil butanóico substituídos como inibidores de nep (endopeptidase neutra) |
| AU2013387996B2 (en) | 2013-04-22 | 2015-12-10 | Cadila Healthcare Limited | A novel composition for nonalcoholic fatty liver disease (NAFLD) |
| MX2015016403A (es) | 2013-05-30 | 2016-04-11 | Cadila Healthcare Ltd | Proceso para la preparacion de pirroles que tienen actividad hipolipidemica e hipocolesterolemica. |
| CN103304502B (zh) * | 2013-06-02 | 2015-03-04 | 张远强 | 一类抗糖尿病化合物、其制备方法和用途 |
| TW201636015A (zh) | 2013-07-05 | 2016-10-16 | 卡地拉保健有限公司 | 協同性組成物 |
| PE20160878A1 (es) | 2013-07-25 | 2016-09-08 | Novartis Ag | Polipeptidos ciclicos para el tratamiento de la insuficiencia cardiaca |
| TW201518323A (zh) | 2013-07-25 | 2015-05-16 | Novartis Ag | 合成ａｐｅｌｉｎ多肽之生物結合物 |
| IN2013MU02470A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 2013-07-25 | 2015-06-26 | Cadila Healthcare Ltd | |
| US10112898B2 (en) | 2013-09-06 | 2018-10-30 | Cadila Healthcare Limited | Process for the preparation of saroglitazar pharmaceutical salts |
| WO2015068156A1 (en) | 2013-11-05 | 2015-05-14 | Ben-Gurion University Of The Negev Research And Development Authority | Compounds for the treatment of diabetes and disease complications arising from same |
| CN103641761A (zh) * | 2013-11-22 | 2014-03-19 | 沈阳化工大学 | 一种维格利汀的制备方法 |
| US9526728B2 (en) | 2014-02-28 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Medical use of a DPP-4 inhibitor |
| EP2915528A1 (en) | 2014-03-06 | 2015-09-09 | Sanovel Ilac Sanayi ve Ticaret A.S. | Vildagliptin formulation process under inert gas atmosphere |
| CN103992257B (zh) * | 2014-05-16 | 2016-03-30 | 苏州天马精细化学品股份有限公司 | 一种维格列汀粗品的纯化方法 |
| CN105439873A (zh) * | 2014-08-20 | 2016-03-30 | 天津药物研究院 | 3-羟基-1-金刚烷胺的制备方法 |
| GB201415598D0 (en) | 2014-09-03 | 2014-10-15 | Univ Birmingham | Elavated Itercranial Pressure Treatment |
| CN105884669B (zh) * | 2014-09-15 | 2020-05-15 | 深圳翰宇药业股份有限公司 | 制备取代的(s)-吡咯烷-2-甲腈及维格列汀的方法 |
| ES2995737T3 (en) | 2015-01-06 | 2025-02-11 | Arena Pharm Inc | Compound for use in treating conditions related to the s1p1 receptor |
| CN104529857B (zh) * | 2015-01-13 | 2016-03-30 | 佛山市赛维斯医药科技有限公司 | 卤代金刚烷酰胺类衍生物、其制备方法和用途 |
| WO2016116842A1 (en) | 2015-01-23 | 2016-07-28 | Novartis Ag | Synthetic apelin fatty acid conjugates with improved half-life |
| JP2018507914A (ja) | 2015-03-09 | 2018-03-22 | インテクリン・セラピューティクス・インコーポレイテッド | 非アルコール性脂肪肝疾患および／またはリポジストロフィーの処置のための方法 |
| CN104761456B (zh) * | 2015-03-10 | 2020-04-10 | 上海威智医药科技有限公司 | 3-氨基-1-金刚烷醇的制备方法 |
| CN104817482B (zh) * | 2015-03-17 | 2017-05-10 | 宁波百思佳医药科技有限公司 | 2‑取代吡咯烷类化合物、制备方法及其在制备维格列汀中的应用 |
| US10301262B2 (en) | 2015-06-22 | 2019-05-28 | Arena Pharmaceuticals, Inc. | Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compund1) for use in SIPI receptor-associated disorders |
| US10385017B2 (en) | 2015-10-14 | 2019-08-20 | Cadila Healthcare Limited | Pyrrole compound, compositions and process for preparation thereof |
| RU2628573C2 (ru) * | 2015-11-27 | 2017-08-21 | Общество с ограниченной ответственностью "Аллель Центр Инновационных Биотехнологий" | Ингибитор дипептидилпептидазы-4 для лечения сахарного диабета 2-го типа |
| MX2018007681A (es) | 2015-12-28 | 2018-11-14 | Wockhardt Ltd | Composicion farmaceutica osmotica oral de vildagliptin. |
| US10155000B2 (en) | 2016-06-10 | 2018-12-18 | Boehringer Ingelheim International Gmbh | Medical use of pharmaceutical combination or composition |
| DE102016116130A1 (de) | 2016-08-30 | 2018-03-01 | Universität Bielefeld | Verfahren zur Herstellung chiraler Aminonitrile |
| WO2018050892A1 (en) | 2016-09-16 | 2018-03-22 | Galenicum Health S.L. | Vildagliptin pharmaceutical compositions |
| JOP20190086A1 (ar) | 2016-10-21 | 2019-04-18 | Novartis Ag | مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب |
| MX382765B (es) | 2016-12-09 | 2025-03-13 | Zydus Lifesciences Ltd | Tratamiento para la colangitis biliar primaria. |
| WO2018162722A1 (en) | 2017-03-09 | 2018-09-13 | Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke | Dpp-4 inhibitors for use in treating bone fractures |
| CN110996951A (zh) | 2017-04-03 | 2020-04-10 | 科赫罗斯生物科学股份有限公司 | 治疗进行性核上性麻痹的PPARγ激动剂 |
| GR1009406B (el) | 2017-10-03 | 2018-11-26 | Φαρματεν Αβεε | Φαρμακευτικο σκευασμα που περιλαμβανει βιλνταγλιπτινη και μεθοδος για την παρασκευη αυτου |
| UY38072A (es) | 2018-02-07 | 2019-10-01 | Novartis Ag | Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos |
| KR102622198B1 (ko) | 2018-03-30 | 2024-01-09 | 한미약품 주식회사 | 빌다글립틴을 함유하는 경구용 고형제제 및 그의 제조 방법 |
| ES2987794T3 (es) | 2018-06-06 | 2024-11-18 | Arena Pharm Inc | Procedimientos de tratamiento de afecciones relacionadas con el receptor S1P1 |
| GR1009644B (el) | 2018-09-25 | 2019-11-12 | Φαρματεν Α.Β.Ε.Ε. | Φαρμακευτικο σκευασμα που περιλαμβανει βιλνταγλιπτινη και μετφορμινη και μεθοδος για την παρασκευη αυτου |
| EP3887363A1 (en) | 2018-11-27 | 2021-10-06 | Novartis AG | Cyclic pentamer compounds as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorder |
| UY38485A (es) | 2018-11-27 | 2020-06-30 | Novartis Ag | Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación |
| JP7657151B2 (ja) | 2018-11-27 | 2025-04-04 | ノバルティス アーゲー | 代謝性障害の処置のためのプロタンパク質コンバターゼスブチリシン／ケキシン９型（ｐｃｓｋ９）阻害剤としての環状ペプチド |
| JP7461735B2 (ja) * | 2019-12-02 | 2024-04-04 | 日本ジェネリック株式会社 | ビルダグリプチン含有錠剤 |
| CN113527167B (zh) * | 2020-04-14 | 2024-01-19 | 威智医药股份有限公司 | 一种维格列汀的生产方法 |
| WO2021234430A1 (en) | 2020-05-17 | 2021-11-25 | Lotus International Pte. Ltd. | Modified release dosage form comprising vildagliptin and process for manufacturing the same |
| WO2022003405A1 (en) | 2020-07-03 | 2022-01-06 | Savoi Guilherme | One-pot process to obtain a pyrrolidine-2-carbonitrile intermediate compound and industrial scale telescopic process to prepare (2s)-1-[n-(3-hydroxyadamantan-1-yl)glycyl]-2-pyrrolidinecarbonitrile (vildagliptin) using same |
| WO2022029220A1 (en) | 2020-08-05 | 2022-02-10 | Ellipses Pharma Ltd | Treatment of cancer using a cyclodextrin-containing polymer-topoisomerase inhibitor conjugate and a parp inhibitor |
| JP2024504328A (ja) * | 2021-01-21 | 2024-01-31 | ザ スクリプス リサーチ インスティテュート | 肺疾患の治療のための肺胞２型細胞増殖の小分子調節因子 |
| WO2023084449A1 (en) | 2021-11-12 | 2023-05-19 | Novartis Ag | Diaminocyclopentylpyridine derivatives for the treatment of a disease or disorder |
| AR127698A1 (es) | 2021-11-23 | 2024-02-21 | Novartis Ag | Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno |
| WO2024241229A1 (en) | 2023-05-24 | 2024-11-28 | Novartis Ag | Naphthyridinone derivatives for the treatment of a disease or disorder |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998019998A2 (en) * | 1996-11-07 | 1998-05-14 | Novartis Ag | N-substituted 2-cyanopyrrolidines |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE296075C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * | ||||
| DE158109C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * | ||||
| FR2572399B1 (fr) * | 1984-10-31 | 1987-01-16 | Panmedica Sa | Nouveaux derives de l'adamantanamine, leurs procedes de preparation et medicaments les contenant |
| JPH0662671B2 (ja) * | 1986-01-17 | 1994-08-17 | 株式会社大塚製薬工場 | プロリン誘導体 |
| WO1990012005A1 (en) * | 1989-04-13 | 1990-10-18 | Japan Tobacco Inc. | New amino acid derivatives having prolylendopeptidase inhibitor activity |
| DE69124371T2 (de) * | 1990-04-14 | 1997-06-12 | New England Medical Center Inc | Typ-iv-dipeptidyl-aminopeptidase-inhibitoren |
| EP1050540B1 (en) * | 1991-10-22 | 2006-12-27 | New England Medical Center Hospitals, Inc. | Inhibitors of dipeptidyl-aminopeptidase type IV |
| PH31294A (en) * | 1992-02-13 | 1998-07-06 | Thomae Gmbh Dr K | Benzimidazolyl derivatives, pharmaceutical compositions containing these compounds and process for preparing them. |
| WO1995011689A1 (en) * | 1993-10-29 | 1995-05-04 | Trustees Of Tufts College | Use of inhibitors of dipeptidyl-aminopeptidase to block entry of hiv into cells |
| PL322706A1 (en) * | 1993-11-09 | 1998-02-16 | Merck & Co Inc | Piperidines, pyrolidines and hexahydro-1h-azepins enhancing growth hormone liberation |
| IL111785A0 (en) * | 1993-12-03 | 1995-01-24 | Ferring Bv | Dp-iv inhibitors and pharmaceutical compositions containing them |
| FR2719049B1 (fr) * | 1994-04-22 | 1996-06-14 | Pasteur Institut | Multireprésentation d'un analogue peptidique du substrat de la DPPIV, notamment de type KPR, afin d'inhiber l'entrée du HIV dans les cellules. |
| US5543396A (en) * | 1994-04-28 | 1996-08-06 | Georgia Tech Research Corp. | Proline phosphonate derivatives |
| AU2790895A (en) * | 1994-06-10 | 1996-01-05 | Universitaire Instelling Antwerpen | Purification of serine protease and synthetic inhibitors thereof |
| AU8377398A (en) * | 1997-06-27 | 1999-01-19 | Penn State Research Foundation, The | Methods and tissue culture media for inducing somatic embryogenesis, (agrobacterium)-mediated transformation and efficient regeneration of cacao plants |
| CA2319195A1 (en) * | 1998-02-02 | 1999-08-05 | Trustees Of Tufts College | Method of regulating glucose metabolism, and reagents related thereto |
| JP2003190202A (ja) * | 2001-12-28 | 2003-07-08 | Yoshinobu Sekizawa | 使い捨てカイロ目的別貼付位置及び禁止位置表示付き下着 |
| EP1511449A2 (en) * | 2002-06-08 | 2005-03-09 | Ian Robert Thomson | Delivery system for a medicament or well-being enhancing composition |
-
1999
- 1999-12-02 CO CO99075802A patent/CO5150173A1/es unknown
- 1999-12-07 PE PE1999001213A patent/PE20001317A1/es not_active IP Right Cessation
- 1999-12-07 AR ARP990106231A patent/AR023719A1/es active IP Right Grant
- 1999-12-07 TW TW088121371A patent/TW509674B/zh not_active IP Right Cessation
- 1999-12-09 JP JP2000586689A patent/JP3681110B2/ja not_active Expired - Lifetime
- 1999-12-09 TR TR2001/01478T patent/TR200101478T2/xx unknown
- 1999-12-09 KR KR10-2001-7007227A patent/KR100509311B1/ko not_active Expired - Lifetime
- 1999-12-09 CA CA002350609A patent/CA2350609C/en not_active Expired - Lifetime
- 1999-12-09 WO PCT/EP1999/009708 patent/WO2000034241A1/en active Search and Examination
- 1999-12-09 DK DK99959396T patent/DK1137635T3/da active
- 1999-12-09 DE DE122008000007C patent/DE122008000007I1/de active Pending
- 1999-12-09 AT AT99959396T patent/ATE307112T1/de active
- 1999-12-09 CN CNB998142026A patent/CN1160330C/zh not_active Expired - Lifetime
- 1999-12-09 SK SK789-2001A patent/SK286635B6/sk not_active IP Right Cessation
- 1999-12-09 MY MYPI99005359A patent/MY123244A/en unknown
- 1999-12-09 HU HU0104495A patent/HU226769B1/hu active Protection Beyond IP Right Term
- 1999-12-09 ES ES99959396T patent/ES2251847T3/es not_active Expired - Lifetime
- 1999-12-09 CZ CZ20012028A patent/CZ299151B6/cs not_active IP Right Cessation
- 1999-12-09 HK HK02100662.5A patent/HK1040394B/en not_active IP Right Cessation
- 1999-12-09 EP EP99959396A patent/EP1137635B1/en not_active Expired - Lifetime
- 1999-12-09 IL IL14309199A patent/IL143091A0/xx active Protection Beyond IP Right Term
- 1999-12-09 RU RU2001118826/04A patent/RU2251544C2/ru active Protection Beyond IP Right Term
- 1999-12-09 KR KR1020057007771A patent/KR20050047561A/ko not_active Ceased
- 1999-12-09 BR BRPI9915985A patent/BRPI9915985B8/pt not_active IP Right Cessation
- 1999-12-09 US US09/458,224 patent/US6166063A/en not_active Expired - Lifetime
- 1999-12-09 ID IDW00200101155A patent/ID28796A/id unknown
- 1999-12-09 DE DE69927844T patent/DE69927844T2/de not_active Expired - Lifetime
- 1999-12-09 NZ NZ511935A patent/NZ511935A/en not_active IP Right Cessation
- 1999-12-09 DE DE122008000017C patent/DE122008000017I1/de active Pending
- 1999-12-09 PL PL348043A patent/PL199443B1/pl unknown
- 1999-12-10 UY UY25843A patent/UY25843A1/es not_active IP Right Cessation
-
2001
- 2001-05-10 IL IL143091A patent/IL143091A/en active Protection Beyond IP Right Term
- 2001-06-05 ZA ZA200104581A patent/ZA200104581B/en unknown
- 2001-06-08 NO NO20012853A patent/NO318741B1/no not_active IP Right Cessation
-
2005
- 2005-01-17 JP JP2005008992A patent/JP2005112864A/ja active Pending
-
2006
- 2006-01-18 CY CY20061100065T patent/CY1105355T1/el unknown
-
2008
- 2008-01-16 LU LU91409C patent/LU91409I2/fr unknown
- 2008-01-17 NL NL300333C patent/NL300333I2/nl unknown
- 2008-01-23 FR FR08C0005C patent/FR08C0005I2/fr active Active
- 2008-01-25 CY CY200800002C patent/CY2008002I1/el unknown
- 2008-01-25 NO NO2008001C patent/NO2008001I1/no not_active IP Right Cessation
- 2008-05-09 NO NO2008004C patent/NO2008004I1/no unknown
- 2008-05-09 LU LU91435C patent/LU91435I2/fr unknown
- 2008-05-12 CY CY2008011C patent/CY2008011I2/el unknown
- 2008-05-14 NL NL300345C patent/NL300345I1/nl unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998019998A2 (en) * | 1996-11-07 | 1998-05-14 | Novartis Ag | N-substituted 2-cyanopyrrolidines |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100509311B1 (ko) | Ｎ-치환된 2-시아노피롤리딘 | |
| EP0937040B1 (en) | N-substituted 2-cyanopyrrolidines | |
| US6172081B1 (en) | Tetrahydroisoquinoline 3-carboxamide derivatives | |
| US6124305A (en) | Use of N-(substituted glycyl)-2-cyanopyrrolidines in inhibiting dipeptidyl peptidase-IV | |
| US6617340B1 (en) | N-(substituted glycyl)-pyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV | |
| MXPA01005817A (en) | N-substituted 2-cyanopyrrolidines | |
| HK1022149B (en) | N-substituted 2-cyanopyrrolidines | |
| MXPA99004281A (en) | N-substituted 2-cyanopyrrolidines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20010609 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| AMND | Amendment | ||
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| AMND | Amendment | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20011207 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20040130 Patent event code: PE09021S01D |
|
| AMND | Amendment | ||
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20041231 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20040130 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |
|
| J201 | Request for trial against refusal decision | ||
| PJ0201 | Trial against decision of rejection |
Patent event date: 20050401 Comment text: Request for Trial against Decision on Refusal Patent event code: PJ02012R01D Patent event date: 20041231 Comment text: Decision to Refuse Application Patent event code: PJ02011S01I Appeal kind category: Appeal against decision to decline refusal Decision date: 20050519 Appeal identifier: 2005101002013 Request date: 20050401 |
|
| A107 | Divisional application of patent | ||
| AMND | Amendment | ||
| PA0104 | Divisional application for international application |
Comment text: Divisional Application for International Patent Patent event code: PA01041R01D Patent event date: 20050502 |
|
| PB0901 | Examination by re-examination before a trial |
Comment text: Amendment to Specification, etc. Patent event date: 20050502 Patent event code: PB09011R02I Comment text: Request for Trial against Decision on Refusal Patent event date: 20050401 Patent event code: PB09011R01I Comment text: Amendment to Specification, etc. Patent event date: 20040630 Patent event code: PB09011R02I Comment text: Amendment to Specification, etc. Patent event date: 20011207 Patent event code: PB09011R02I Comment text: Amendment to Specification, etc. Patent event date: 20010705 Patent event code: PB09011R02I |
|
| B701 | Decision to grant | ||
| PB0701 | Decision of registration after re-examination before a trial |
Patent event date: 20050519 Comment text: Decision to Grant Registration Patent event code: PB07012S01D Patent event date: 20050512 Comment text: Transfer of Trial File for Re-examination before a Trial Patent event code: PB07011S01I |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20050811 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20050812 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration | ||
| J251 | Registration of extension of term of patent right | ||
| PR1001 | Payment of annual fee |
Payment date: 20080808 Start annual number: 4 End annual number: 4 |
|
| PR1001 | Payment of annual fee |
Payment date: 20090807 Start annual number: 5 End annual number: 5 |
|
| PR1001 | Payment of annual fee |
Payment date: 20100811 Start annual number: 6 End annual number: 6 |
|
| PR1001 | Payment of annual fee |
Payment date: 20110725 Start annual number: 7 End annual number: 7 |
|
| FPAY | Annual fee payment |
Payment date: 20120727 Year of fee payment: 8 |
|
| PR1001 | Payment of annual fee |
Payment date: 20120727 Start annual number: 8 End annual number: 8 |
|
| FPAY | Annual fee payment |
Payment date: 20130723 Year of fee payment: 9 |
|
| PR1001 | Payment of annual fee |
Payment date: 20130723 Start annual number: 9 End annual number: 9 |
|
| FPAY | Annual fee payment |
Payment date: 20140722 Year of fee payment: 10 |
|
| PR1001 | Payment of annual fee |
Payment date: 20140722 Start annual number: 10 End annual number: 10 |
|
| FPAY | Annual fee payment |
Payment date: 20150716 Year of fee payment: 11 |
|
| PR1001 | Payment of annual fee |
Payment date: 20150716 Start annual number: 11 End annual number: 11 |
|
| FPAY | Annual fee payment |
Payment date: 20160720 Year of fee payment: 12 |
|
| PR1001 | Payment of annual fee |
Payment date: 20160720 Start annual number: 12 End annual number: 12 |
|
| J252 | Request for trial |
Free format text: TRIAL NUMBER: 2017100002256; INVALIDATION TRIAL FOR REGISTRATION OF EXTENSION OF TERM OF PATENT RIGHT FOR INVALIDATION OF EXTENSION OF TERM Free format text: TRIAL NUMBER: 2017100002257; INVALIDATION TRIAL FOR REGISTRATION OF EXTENSION OF TERM OF PATENT RIGHT FOR INVALIDATION OF EXTENSION OF TERM |
|
| PJ0205 | Invalidation trial for registration of extension of term of patent right |
Decision date: 20190228 Appeal identifier: 2017100002257 Appeal kind category: Invalidation of Extension of Term Request date: 20170714 Comment text: Request for Trial Patent event code: PJ02052R01D Patent event date: 20170714 Comment text: Registration of Extension of Term of Patent Right Patent event code: PJ02051S01I Patent event date: 20080714 Decision date: 20190228 Appeal identifier: 2017100002256 Appeal kind category: Invalidation of Extension of Term Request date: 20170714 |
|
| FPAY | Annual fee payment |
Payment date: 20170804 Year of fee payment: 13 |
|
| PR1001 | Payment of annual fee |
Payment date: 20170804 Start annual number: 13 End annual number: 13 |
|
| PR1001 | Payment of annual fee |
Payment date: 20180730 Start annual number: 14 End annual number: 14 |
|
| J206 | Request for trial to confirm the scope of a patent right | ||
| J252 | Request for trial |
Free format text: TRIAL NUMBER: 2018100002430; INVALIDATION TRIAL FOR REGISTRATION OF EXTENSION OF TERM OF PATENT RIGHT FOR INVALIDATION OF EXTENSION OF TERM |
|
| PJ0205 | Invalidation trial for registration of extension of term of patent right |
Comment text: Request for Trial Patent event code: PJ02052R01D Patent event date: 20180731 Comment text: Registration of Extension of Term of Patent Right Patent event code: PJ02051S01I Patent event date: 20080714 Decision date: 20190228 Appeal identifier: 2018100002430 Appeal kind category: Invalidation of Extension of Term Request date: 20180731 |
|
| PJ0206 | Trial to confirm the scope of a patent |
Patent event code: PJ02062R01D Patent event date: 20180731 Comment text: Request for Trial Patent event code: PJ02061E01I Patent event date: 20050811 Comment text: Registration of Establishment Decision date: 20190930 Request date: 20180731 Appeal identifier: 2018100002431 Appeal kind category: Confirmation of the scope of right_defensive |
|
| J301 | Trial decision |
Free format text: TRIAL NUMBER: 2017100002257; TRIAL DECISION FOR INVALIDATION OF EXTENSION OF TERM REQUESTED 20170714 Effective date: 20190228 Free format text: TRIAL NUMBER: 2017100002256; TRIAL DECISION FOR INVALIDATION OF EXTENSION OF TERM REQUESTED 20170714 Effective date: 20190228 |
|
| PJ1301 | Trial decision |
Appeal kind category: Invalidation of Extension of Term Request date: 20180731 Decision date: 20190228 Appeal identifier: 2018100002430 Appeal kind category: Invalidation of Extension of Term Request date: 20170714 Decision date: 20190228 Appeal identifier: 2017100002257 Patent event code: PJ13011S05D Patent event date: 20190228 Comment text: Trial Decision on Invalidation (Patent, Utility Model, Industrial Design) Appeal kind category: Invalidation of Extension of Term Request date: 20170714 Decision date: 20190228 Appeal identifier: 2017100002256 |
|
| PJ2001 | Appeal |
Appeal kind category: Invalidation of Extension of Term Decision date: 20201029 Appeal identifier: 2019200003595 Request date: 20190503 Patent event date: 20190228 Comment text: Trial Decision on Invalidation (Patent, Utility Model, Industrial Design) Patent event code: PJ20011S05I Appeal kind category: Invalidation of Extension of Term Decision date: 20201029 Appeal identifier: 2019200003588 Request date: 20190503 |
|
| FPAY | Annual fee payment |
Payment date: 20190729 Year of fee payment: 15 |
|
| PR1001 | Payment of annual fee |
Payment date: 20190729 Start annual number: 15 End annual number: 15 |
|
| J301 | Trial decision |
Free format text: TRIAL NUMBER: 2018100002431; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20180731 Effective date: 20190930 |
|
| PJ1301 | Trial decision |
Patent event code: PJ13011S02D Patent event date: 20190930 Comment text: Trial Decision for Confirmation of the Scope of a Right (Patent, Utility Model, Industrial Design) Appeal kind category: Confirmation of the scope of right_defensive Request date: 20180731 Decision date: 20190930 Appeal identifier: 2018100002431 |
|
| J206 | Request for trial to confirm the scope of a patent right | ||
| PJ0206 | Trial to confirm the scope of a patent |
Decision date: 20200701 Request date: 20191101 Appeal identifier: 2019100003448 Appeal kind category: Confirmation of the scope of right_defensive Decision date: 20200701 Request date: 20191101 Appeal identifier: 2019100003447 Appeal kind category: Confirmation of the scope of right_defensive Decision date: 20200701 Request date: 20191101 Appeal identifier: 2019100003446 Appeal kind category: Confirmation of the scope of right_defensive Patent event code: PJ02062R01D Patent event date: 20191101 Comment text: Request for Trial Patent event code: PJ02061E01I Patent event date: 20050811 Comment text: Registration of Establishment Decision date: 20200701 Request date: 20191101 Appeal identifier: 2019100003445 Appeal kind category: Confirmation of the scope of right_defensive |
|
| J206 | Request for trial to confirm the scope of a patent right | ||
| PJ0206 | Trial to confirm the scope of a patent |
Decision date: 20200701 Request date: 20191105 Appeal identifier: 2019100003488 Appeal kind category: Confirmation of the scope of right_defensive Decision date: 20200701 Request date: 20191105 Appeal identifier: 2019100003487 Appeal kind category: Confirmation of the scope of right_defensive Decision date: 20200701 Request date: 20191105 Appeal identifier: 2019100003486 Appeal kind category: Confirmation of the scope of right_defensive Patent event code: PJ02062R01D Patent event date: 20191105 Comment text: Request for Trial Patent event code: PJ02061E01I Patent event date: 20050811 Comment text: Registration of Establishment Decision date: 20200701 Request date: 20191105 Appeal identifier: 2019100003484 Appeal kind category: Confirmation of the scope of right_defensive |
|
| J206 | Request for trial to confirm the scope of a patent right | ||
| PJ0206 | Trial to confirm the scope of a patent |
Patent event code: PJ02062R01D Patent event date: 20191128 Comment text: Request for Trial Patent event code: PJ02061E01I Patent event date: 20050811 Comment text: Registration of Establishment Decision date: 20200701 Request date: 20191128 Appeal identifier: 2019100003800 Appeal kind category: Confirmation of the scope of right_defensive |
|
| J206 | Request for trial to confirm the scope of a patent right | ||
| PJ0206 | Trial to confirm the scope of a patent |
Decision date: 20200701 Request date: 20191211 Appeal identifier: 2019100003967 Appeal kind category: Confirmation of the scope of right_defensive Decision date: 20200701 Request date: 20191211 Appeal identifier: 2019100003966 Appeal kind category: Confirmation of the scope of right_defensive Decision date: 20200701 Request date: 20191211 Appeal identifier: 2019100003965 Appeal kind category: Confirmation of the scope of right_defensive Decision date: 20200701 Request date: 20191211 Appeal identifier: 2019100003964 Appeal kind category: Confirmation of the scope of right_defensive Decision date: 20200701 Request date: 20191211 Appeal identifier: 2019100003963 Appeal kind category: Confirmation of the scope of right_defensive Decision date: 20200701 Request date: 20191211 Appeal identifier: 2019100003962 Appeal kind category: Confirmation of the scope of right_defensive Decision date: 20200701 Request date: 20191211 Appeal identifier: 2019100003961 Appeal kind category: Confirmation of the scope of right_defensive Patent event code: PJ02062R01D Patent event date: 20191211 Comment text: Request for Trial Patent event code: PJ02061E01I Patent event date: 20050811 Comment text: Registration of Establishment Decision date: 20200701 Request date: 20191211 Appeal identifier: 2019100003960 Appeal kind category: Confirmation of the scope of right_defensive |
|
| J206 | Request for trial to confirm the scope of a patent right | ||
| PJ0206 | Trial to confirm the scope of a patent |
Decision date: 20210415 Request date: 20200605 Appeal identifier: 2020100001730 Appeal kind category: Confirmation of the scope of right_defensive Decision date: 20210118 Request date: 20200605 Appeal identifier: 2020100001729 Appeal kind category: Confirmation of the scope of right_defensive Decision date: 20201008 Request date: 20200605 Appeal identifier: 2020100001728 Appeal kind category: Confirmation of the scope of right_defensive Decision date: 20200827 Request date: 20200605 Appeal identifier: 2020100001727 Appeal kind category: Confirmation of the scope of right_defensive Decision date: 20210304 Request date: 20200605 Appeal identifier: 2020100001726 Appeal kind category: Confirmation of the scope of right_defensive Decision date: 20201202 Request date: 20200605 Appeal identifier: 2020100001725 Appeal kind category: Confirmation of the scope of right_defensive Decision date: 20200901 Request date: 20200605 Appeal identifier: 2020100001724 Appeal kind category: Confirmation of the scope of right_defensive Patent event code: PJ02062R01D Patent event date: 20200605 Comment text: Request for Trial Patent event code: PJ02061E01I Patent event date: 20050811 Comment text: Registration of Establishment Decision date: 20200827 Request date: 20200605 Appeal identifier: 2020100001723 Appeal kind category: Confirmation of the scope of right_defensive |
|
| J301 | Trial decision |
Free format text: TRIAL NUMBER: 2019100003486; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20191105 Effective date: 20200701 Free format text: TRIAL NUMBER: 2019100003962; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20191211 Effective date: 20200701 Free format text: TRIAL NUMBER: 2019100003961; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20191211 Effective date: 20200701 Free format text: TRIAL NUMBER: 2019100003966; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20191211 Effective date: 20200701 Free format text: TRIAL NUMBER: 2019100003447; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20191101 Effective date: 20200701 Free format text: TRIAL NUMBER: 2019100003963; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20191211 Effective date: 20200701 Free format text: TRIAL NUMBER: 2019100003487; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20191105 Effective date: 20200701 Free format text: TRIAL NUMBER: 2019100003448; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20191101 Effective date: 20200701 Free format text: TRIAL NUMBER: 2019100003488; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20191105 Effective date: 20200701 Free format text: TRIAL NUMBER: 2019100003965; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20191211 Effective date: 20200701 Free format text: TRIAL NUMBER: 2019100003960; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20191211 Effective date: 20200701 Free format text: TRIAL NUMBER: 2019100003446; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20191101 Effective date: 20200701 Free format text: TRIAL NUMBER: 2019100003800; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20191128 Effective date: 20200701 Free format text: TRIAL NUMBER: 2019100003445; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20191101 Effective date: 20200701 Free format text: TRIAL NUMBER: 2019100003484; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20191105 Effective date: 20200701 Free format text: TRIAL NUMBER: 2019100003964; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20191211 Effective date: 20200701 Free format text: TRIAL NUMBER: 2019100003967; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20191211 Effective date: 20200701 |
|
| PJ1301 | Trial decision |
Appeal kind category: Confirmation of the scope of right_defensive Request date: 20191211 Decision date: 20200701 Appeal identifier: 2019100003967 Appeal kind category: Confirmation of the scope of right_defensive Request date: 20191211 Decision date: 20200701 Appeal identifier: 2019100003966 Appeal kind category: Confirmation of the scope of right_defensive Request date: 20191211 Decision date: 20200701 Appeal identifier: 2019100003965 Appeal kind category: Confirmation of the scope of right_defensive Request date: 20191211 Decision date: 20200701 Appeal identifier: 2019100003964 Appeal kind category: Confirmation of the scope of right_defensive Request date: 20191211 Decision date: 20200701 Appeal identifier: 2019100003963 Appeal kind category: Confirmation of the scope of right_defensive Request date: 20191211 Decision date: 20200701 Appeal identifier: 2019100003962 Appeal kind category: Confirmation of the scope of right_defensive Request date: 20191211 Decision date: 20200701 Appeal identifier: 2019100003961 Appeal kind category: Confirmation of the scope of right_defensive Request date: 20191211 Decision date: 20200701 Appeal identifier: 2019100003960 Appeal kind category: Confirmation of the scope of right_defensive Request date: 20191128 Decision date: 20200701 Appeal identifier: 2019100003800 Appeal kind category: Confirmation of the scope of right_defensive Request date: 20191105 Decision date: 20200701 Appeal identifier: 2019100003488 Appeal kind category: Confirmation of the scope of right_defensive Request date: 20191105 Decision date: 20200701 Appeal identifier: 2019100003487 Appeal kind category: Confirmation of the scope of right_defensive Request date: 20191105 Decision date: 20200701 Appeal identifier: 2019100003486 Appeal kind category: Confirmation of the scope of right_defensive Request date: 20191105 Decision date: 20200701 Appeal identifier: 2019100003484 Appeal kind category: Confirmation of the scope of right_defensive Request date: 20191101 Decision date: 20200701 Appeal identifier: 2019100003448 Appeal kind category: Confirmation of the scope of right_defensive Request date: 20191101 Decision date: 20200701 Appeal identifier: 2019100003447 Appeal kind category: Confirmation of the scope of right_defensive Request date: 20191101 Decision date: 20200701 Appeal identifier: 2019100003446 Patent event code: PJ13011S02D Patent event date: 20200701 Comment text: Trial Decision for Confirmation of the Scope of a Right (Patent, Utility Model, Industrial Design) Appeal kind category: Confirmation of the scope of right_defensive Request date: 20191101 Decision date: 20200701 Appeal identifier: 2019100003445 |
|
| PR1001 | Payment of annual fee |
Payment date: 20200730 Start annual number: 16 End annual number: 16 |
|
| J301 | Trial decision |
Free format text: TRIAL NUMBER: 2020100001723; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20200605 Effective date: 20200827 Free format text: TRIAL NUMBER: 2020100001727; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20200605 Effective date: 20200827 |
|
| PJ1301 | Trial decision |
Appeal kind category: Confirmation of the scope of right_defensive Request date: 20200605 Decision date: 20200827 Appeal identifier: 2020100001727 Patent event code: PJ13011S02D Patent event date: 20200827 Comment text: Trial Decision for Confirmation of the Scope of a Right (Patent, Utility Model, Industrial Design) Appeal kind category: Confirmation of the scope of right_defensive Request date: 20200605 Decision date: 20200827 Appeal identifier: 2020100001723 |
|
| J301 | Trial decision |
Free format text: TRIAL NUMBER: 2020100001724; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20200605 Effective date: 20200901 |
|
| PJ1301 | Trial decision |
Patent event code: PJ13011S02D Patent event date: 20200901 Comment text: Trial Decision for Confirmation of the Scope of a Right (Patent, Utility Model, Industrial Design) Appeal kind category: Confirmation of the scope of right_defensive Request date: 20200605 Decision date: 20200901 Appeal identifier: 2020100001724 |
|
| J301 | Trial decision |
Free format text: TRIAL NUMBER: 2020100001728; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20200605 Effective date: 20201008 |
|
| PJ1301 | Trial decision |
Patent event code: PJ13011S02D Patent event date: 20201008 Comment text: Trial Decision for Confirmation of the Scope of a Right (Patent, Utility Model, Industrial Design) Appeal kind category: Confirmation of the scope of right_defensive Request date: 20200605 Decision date: 20201008 Appeal identifier: 2020100001728 |
|
| PJ2002 | Appeal before the supreme court |
Request date: 20201125 Appeal identifier: 2020300011752 Appeal kind category: Invalidation of Extension of Term Decision date: 20211028 Comment text: Trial Decision for Confirmation of the Scope of a Right (Patent, Utility Model, Industrial Design) Patent event date: 20201008 Patent event code: PJ20021S02I Comment text: Trial Decision for Confirmation of the Scope of a Right (Patent, Utility Model, Industrial Design) Patent event date: 20200901 Patent event code: PJ20021S02I Comment text: Trial Decision for Confirmation of the Scope of a Right (Patent, Utility Model, Industrial Design) Patent event date: 20200827 Patent event code: PJ20021S02I Comment text: Trial Decision for Confirmation of the Scope of a Right (Patent, Utility Model, Industrial Design) Patent event date: 20200701 Patent event code: PJ20021S02I Comment text: Trial Decision for Confirmation of the Scope of a Right (Patent, Utility Model, Industrial Design) Patent event date: 20190930 Patent event code: PJ20021S02I Comment text: Trial Decision on Invalidation (Patent, Utility Model, Industrial Design) Patent event date: 20190228 Patent event code: PJ20021S05I Request date: 20201125 Appeal identifier: 2020300011745 Appeal kind category: Invalidation of Extension of Term Decision date: 20211028 |
|
| J301 | Trial decision |
Free format text: TRIAL NUMBER: 2020100001725; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20200605 Effective date: 20201202 |
|
| PJ1301 | Trial decision |
Patent event code: PJ13011S02D Patent event date: 20201202 Comment text: Trial Decision for Confirmation of the Scope of a Right (Patent, Utility Model, Industrial Design) Appeal kind category: Confirmation of the scope of right_defensive Request date: 20200605 Decision date: 20201202 Appeal identifier: 2020100001725 |
|
| J302 | Written judgement (patent court) |
Free format text: TRIAL NUMBER: 2019200003588; JUDGMENT (PATENT COURT) FOR INVALIDATION OF EXTENSION OF TERM REQUESTED 20190503 Effective date: 20201029 Free format text: TRIAL NUMBER: 2019200003595; JUDGMENT (PATENT COURT) FOR INVALIDATION OF EXTENSION OF TERM REQUESTED 20190503 Effective date: 20201029 |
|
| PJ1302 | Judgment (patent court) |
Request date: 20190503 Decision date: 20201029 Appeal identifier: 2019200003595 Appeal kind category: Invalidation of Extension of Term Patent event date: 20201203 Comment text: Written Judgment (Patent Court) Patent event code: PJ13021S01D Request date: 20190503 Decision date: 20201029 Appeal identifier: 2019200003588 Appeal kind category: Invalidation of Extension of Term |
|
| J301 | Trial decision |
Free format text: TRIAL NUMBER: 2020100001729; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20200605 Effective date: 20210118 |
|
| PJ1301 | Trial decision |
Patent event code: PJ13011S02D Patent event date: 20210118 Comment text: Trial Decision for Confirmation of the Scope of a Right (Patent, Utility Model, Industrial Design) Appeal kind category: Confirmation of the scope of right_defensive Request date: 20200605 Decision date: 20210118 Appeal identifier: 2020100001729 |
|
| J301 | Trial decision |
Free format text: TRIAL NUMBER: 2020100001726; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20200605 Effective date: 20210304 |
|
| PJ1301 | Trial decision |
Patent event code: PJ13011S02D Patent event date: 20210304 Comment text: Trial Decision for Confirmation of the Scope of a Right (Patent, Utility Model, Industrial Design) Appeal kind category: Confirmation of the scope of right_defensive Request date: 20200605 Decision date: 20210304 Appeal identifier: 2020100001726 |
|
| PJ1301 | Trial decision |
Patent event code: PJ13011S02D Patent event date: 20210415 Comment text: Trial Decision for Confirmation of the Scope of a Right (Patent, Utility Model, Industrial Design) Appeal kind category: Confirmation of the scope of right_defensive Request date: 20200605 Decision date: 20210415 Appeal identifier: 2020100001730 |
|
| PR1001 | Payment of annual fee |
Payment date: 20210728 Start annual number: 17 End annual number: 17 |
|
| J303 | Written judgement (supreme court) |
Free format text: TRIAL NUMBER: 2020300011752; JUDGMENT (SUPREME COURT) FOR INVALIDATION OF EXTENSION OF TERM REQUESTED 20201125 Effective date: 20211028 Free format text: TRIAL NUMBER: 2020300011745; JUDGMENT (SUPREME COURT) FOR INVALIDATION OF EXTENSION OF TERM REQUESTED 20201125 Effective date: 20211028 |
|
| PJ1303 | Judgment (supreme court) |
Decision date: 20211028 Appeal kind category: Invalidation of Extension of Term Request date: 20201125 Appeal identifier: 2020300011752 Comment text: Written Judgment (Supreme Court) Patent event date: 20211109 Patent event code: PJ13031S01D Decision date: 20211028 Appeal kind category: Invalidation of Extension of Term Request date: 20201125 Appeal identifier: 2020300011745 |
|
| PJ2201 | Remand (intellectual property tribunal) |
Request date: 20211109 Appeal kind category: Invalidation of Extension of Term Appeal identifier: 2021130000115 Decision date: 20220502 Request date: 20211109 Appeal kind category: Invalidation of Extension of Term Appeal identifier: 2021130000114 Decision date: 20220502 Request date: 20211109 Appeal kind category: Invalidation of Extension of Term Appeal identifier: 2021130000113 Decision date: 20220502 |
|
| J206 | Request for trial to confirm the scope of a patent right | ||
| PJ0206 | Trial to confirm the scope of a patent |
Decision date: 20220504 Request date: 20220113 Appeal identifier: 2022100000129 Appeal kind category: Confirmation of the scope of right_affirmative Request date: 20220113 Appeal identifier: 2022100000128 Appeal kind category: Confirmation of the scope of right_affirmative Request date: 20220113 Appeal identifier: 2022100000127 Appeal kind category: Confirmation of the scope of right_affirmative Request date: 20220113 Appeal identifier: 2022100000126 Appeal kind category: Confirmation of the scope of right_affirmative Request date: 20220113 Appeal identifier: 2022100000125 Appeal kind category: Confirmation of the scope of right_affirmative Patent event code: PJ02062R01D Patent event date: 20220113 Comment text: Request for Trial Patent event code: PJ02061E01I Patent event date: 20050811 Comment text: Registration of Establishment Request date: 20220113 Appeal identifier: 2022100000124 Appeal kind category: Confirmation of the scope of right_affirmative |
|
| PC1801 | Expiration of term | ||
| J301 | Trial decision |
Free format text: TRIAL NUMBER: 2021130000114; TRIAL DECISION FOR INVALIDATION OF EXTENSION OF TERM REQUESTED 20211109 Effective date: 20220502 Free format text: TRIAL NUMBER: 2021130000113; TRIAL DECISION FOR INVALIDATION OF EXTENSION OF TERM REQUESTED 20211109 Effective date: 20220502 |
|
| PJ1301 | Trial decision |
Appeal kind category: Invalidation of Extension of Term Request date: 20211109 Decision date: 20220502 Appeal identifier: 2021130000115 Appeal kind category: Invalidation of Extension of Term Request date: 20211109 Decision date: 20220502 Appeal identifier: 2021130000114 Patent event code: PJ13011S09D Patent event date: 20220502 Comment text: Trial Decision on Final Judgment on Revocation Appeal kind category: Invalidation of Extension of Term Request date: 20211109 Decision date: 20220502 Appeal identifier: 2021130000113 |
|
| PJ1201 | Withdrawal of trial |
Patent event code: PJ12011R01D Patent event date: 20220504 Comment text: Written Withdrawal of Request for Trial Appeal identifier: 2022100000129 Request date: 20220113 Appeal kind category: Confirmation of the scope of right_affirmative Decision date: 20220504 |
|
| PJ2001 | Appeal |
Patent event date: 20220502 Comment text: Trial Decision on Final Judgment on Revocation Patent event code: PJ20011S09I Patent event date: 20210415 Comment text: Trial Decision for Confirmation of the Scope of a Right (Patent, Utility Model, Industrial Design) Patent event code: PJ20011S02I Patent event date: 20210304 Comment text: Trial Decision for Confirmation of the Scope of a Right (Patent, Utility Model, Industrial Design) Patent event code: PJ20011S02I Patent event date: 20210118 Comment text: Trial Decision for Confirmation of the Scope of a Right (Patent, Utility Model, Industrial Design) Patent event code: PJ20011S02I Patent event date: 20201202 Comment text: Trial Decision for Confirmation of the Scope of a Right (Patent, Utility Model, Industrial Design) Patent event code: PJ20011S02I Patent event date: 20201008 Comment text: Trial Decision for Confirmation of the Scope of a Right (Patent, Utility Model, Industrial Design) Patent event code: PJ20011S02I Patent event date: 20200901 Comment text: Trial Decision for Confirmation of the Scope of a Right (Patent, Utility Model, Industrial Design) Patent event code: PJ20011S02I Patent event date: 20200827 Comment text: Trial Decision for Confirmation of the Scope of a Right (Patent, Utility Model, Industrial Design) Patent event code: PJ20011S02I Patent event date: 20200701 Comment text: Trial Decision for Confirmation of the Scope of a Right (Patent, Utility Model, Industrial Design) Patent event code: PJ20011S02I Patent event date: 20190930 Comment text: Trial Decision for Confirmation of the Scope of a Right (Patent, Utility Model, Industrial Design) Patent event code: PJ20011S02I Patent event date: 20190228 Comment text: Trial Decision on Invalidation (Patent, Utility Model, Industrial Design) Patent event code: PJ20011S05I Appeal kind category: Invalidation of Extension of Term Appeal identifier: 2022200003533 Request date: 20220531 |
|
| PJ2001 | Appeal |
Patent event date: 20220502 Comment text: Trial Decision on Final Judgment on Revocation Patent event code: PJ20011S09I Patent event date: 20210415 Comment text: Trial Decision for Confirmation of the Scope of a Right (Patent, Utility Model, Industrial Design) Patent event code: PJ20011S02I Patent event date: 20210304 Comment text: Trial Decision for Confirmation of the Scope of a Right (Patent, Utility Model, Industrial Design) Patent event code: PJ20011S02I Patent event date: 20210118 Comment text: Trial Decision for Confirmation of the Scope of a Right (Patent, Utility Model, Industrial Design) Patent event code: PJ20011S02I Patent event date: 20201202 Comment text: Trial Decision for Confirmation of the Scope of a Right (Patent, Utility Model, Industrial Design) Patent event code: PJ20011S02I Patent event date: 20201008 Comment text: Trial Decision for Confirmation of the Scope of a Right (Patent, Utility Model, Industrial Design) Patent event code: PJ20011S02I Patent event date: 20200901 Comment text: Trial Decision for Confirmation of the Scope of a Right (Patent, Utility Model, Industrial Design) Patent event code: PJ20011S02I Patent event date: 20200827 Comment text: Trial Decision for Confirmation of the Scope of a Right (Patent, Utility Model, Industrial Design) Patent event code: PJ20011S02I Patent event date: 20200701 Comment text: Trial Decision for Confirmation of the Scope of a Right (Patent, Utility Model, Industrial Design) Patent event code: PJ20011S02I Patent event date: 20190930 Comment text: Trial Decision for Confirmation of the Scope of a Right (Patent, Utility Model, Industrial Design) Patent event code: PJ20011S02I Patent event date: 20190228 Comment text: Trial Decision on Invalidation (Patent, Utility Model, Industrial Design) Patent event code: PJ20011S05I Appeal kind category: Invalidation of Extension of Term Appeal identifier: 2022200003557 Request date: 20220602 |
|
| J301 | Trial decision |
Free format text: TRIAL NUMBER: 2022100000127; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_AFFIRMATIVE REQUESTED 20220113 Effective date: 20230412 Free format text: TRIAL NUMBER: 2022100000126; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_AFFIRMATIVE REQUESTED 20220113 Effective date: 20230412 Free format text: TRIAL NUMBER: 2022100000125; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_AFFIRMATIVE REQUESTED 20220113 Effective date: 20230412 Free format text: TRIAL NUMBER: 2022100000124; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_AFFIRMATIVE REQUESTED 20220113 Effective date: 20230412 |
|
| PJ1301 | Trial decision |
Appeal kind category: Confirmation of the scope of right_affirmative Request date: 20220113 Decision date: 20230412 Appeal identifier: 2022100000127 Appeal kind category: Confirmation of the scope of right_affirmative Request date: 20220113 Decision date: 20230412 Appeal identifier: 2022100000126 Appeal kind category: Confirmation of the scope of right_affirmative Request date: 20220113 Decision date: 20230412 Appeal identifier: 2022100000125 Patent event code: PJ13011S02D Patent event date: 20230412 Comment text: Trial Decision for Confirmation of the Scope of a Right (Patent, Utility Model, Industrial Design) Appeal kind category: Confirmation of the scope of right_affirmative Request date: 20220113 Decision date: 20230412 Appeal identifier: 2022100000124 |